Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00698087 | Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B | PHASE3 | COMPLETED | 60 | — | — | Jan 1, 1995 | Feb 1, 1996 | Jun 16, 2008 | 1 | Austria |
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Group C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MPL-Adjuvanted recombinant hepatitis B vaccine | BIOLOGICAL | Intramuscular injection, 2 or 3 doses, 2 different formulations |
| Engerix™-B | BIOLOGICAL | Intramuscular injection, 2 or 3 doses |
Inclusion Criteria: * Between 18 and 40 years old. * Written informed consent will have been obtained from the subjects. * Good physical condition as established by physical examination and history taking at the time of entry. * Female participants will avoid becoming pregnant during the study peri...